Experimental cancer cocktails show promise, but study halted early
NCT ID NCT04000529
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was terminated, so full results are not available, but the data may guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TNO155 (a drug) combined with either spartalizumab (an immunotherapy) or ribociclib (a targeted therapy)
- What this could lead to
- If successful, this could point toward new combination treatments for several advanced cancers, including lung, head and neck, and colorectal cancers.
- What could go wrong
- This was a very early (Phase 1) study that was terminated, so results are limited. The combinations may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Westmead, New South Wales, 2145, Australia
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Cologne, 50937, Germany
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Valencia, Valencia, 46010, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Your gut bacteria might reveal hidden cancer risk